Description: |
AN-2690, a broad-spectrum drug, is a very promising candidate for treatment of ungual and periungual infections with improved nail penetration and low keratin binding. AN-2690 is an antifungal agent with activity against Trichophyton species. AN-2690 inhibits yeast cytoplasmic leucyl-tRNA synthetase by Formation of a stable tRNA(Leu)-AN2690 adduct in the editing site of the enzyme. AN-2690 is currently in clinical trials For onychomycosis topical treatment.For the detailed information of AN-2690(Tavaborole), the solubility of AN-2690(Tavaborole) in water, the solubility of AN-2690(Tavaborole) in DMSO, the solubility of AN-2690(Tavaborole) in PBS buffer, the animal experiment (test) of AN-2690(Tavaborole), the cell expriment (test) of AN-2690(Tavaborole), the in vivo, in vitro and clinical trial test of AN-2690(Tavaborole), the EC50, IC50,and Affinity of AN-2690(Tavaborole), Please contact DC Chemicals. |